PPCH - Propanc Health Group Corporation

PPCH Company Description
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc, together with its scientific and oncology consultants, has developed a rational, composite formulation of anti-cancer compounds which together exert a number of anti-cancer actions. Propanc's leading products are novel, patented formulations based on proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects, Propanc intends to progress their lead product along the rigorous, formal non-clinical and clinical development pathway required to obtain regulatory approval to market its proenzyme formulation. Propanc intends to undertake development of manufacturing, formal non-clinical studies and then Phase I, II and III clinical trials in order to generate the quality, safety and efficacy data required for regulatory approval. For more information, please visit: http://www.propanc.com




PPCH Products and Services
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc was established in 2007 and located in Melbourne, Australia.

Highlights
Targeted therapy for metastatic cancer: Global demand for effective, safe and easy to administer cancer treatments increasing rapidly.

Expansive market demand: Seeking worldwide regulatory approval in several indications, targeting tumor types where few treatment options exist.

Multiple mechanisms of action: Our lead product exerts multiple effects inhibiting tumor growth & blood supply, and stopping it spreading. R&D may identify opportunities for developing new compounds.

Encouraging patient data: 15 years of scientific research and clinical experience suggests our lead product may be an effective treatment against cancer and warrants further development.

Unique intellectual property: Propanc is building an IP portfolio around our scientific understanding of the effects of proenzymes in cancer, new formulations, new routes of
administration and potential new targets

$PPCH - after hour Friday News -Targets Cancer Patient Trials in 2015
MELBOURNE, Australia, May 16, 2014 (GLOBE NEWSWIRE) -- Propanc Health Group Corporation (PPCH) ("Propanc Health Group," "Propanc" or "the Company"), a developmental stage a healthcare company focused on new cancer treatments for patients with solid tumors, today announced its key strategic objectives for the development of its lead product, PRP. This Company is now refocusing the preferred route of administration to intravenous (I.V.) injection. They are now targeting 2015 to prepare for and initiate human trials in patients with advanced colorectal and/or pancreatic cancers.

Dr Kenyon, Chief Scientific Officer of Propanc Health Group, states, "After a detailed strategic review of our scientific and preclinical research, our development team determined I.V. injection as the preferred route of administration. This approach would be the best way to maximise results in future patient trials, by ensuring maximum exposure of the drug to the tumor site."

James Nathanielsz, Chief Executive Officer of Propanc Health Group, said, "We believe this will help us to improve the results already observed in a Compassionate Use Study conducted by Dr Kenyon at the Dove Clinic (UK). We were able to extend life in a number of terminally ill patients, free from the serious side effects normally observed during conventional treatment methods."

Based on the Company's strategic review, Propanc Health Group will conduct a number of animal studies in various tumor models. This will identify a target dose for future patient trials. "Once we have assessed and identified the most effective dose in animals, we plan to meet with the FDA (Food and Drug Administration), to discuss and agree upon the planned formal preclinical program to support an Investigational New Drug Application (IND) to commence human trials in 2015," said Professor Klaus Kutz, Chief Medical Officer at Propanc Health Group. "Depending on the final indication selected for our initial patient trials, we may also seek Orphan Drug Designation for our treatment given the novelty of our proenzyme formulation and depending on the size of the target patient population we propose for trials."

The Company is seeking to complete the relevant animal studies and undertake preparation for patient trials next year. "Undertaking these development activities is a critical step for our future plans for the Company," James Nathanielsz, CEO of Propanc Health Group acknowledged. "Our attention will now turn toward raising the capital needed to complete these activities."
Propanc Health Group aims to fast-track the development of proenzyme-related oncology products into clinical trials, initially for colorectal and pancreatic tumors. The world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by the year 2015, according to Global Analyst Reports.

About Propanc Health Group Corporation
Propanc Health Group Corporation is a development stage healthcare company whose current focus is the development of new cancer treatments for patients with solid tumors such as pancreatic and colorectal cancer. Propanc, together with its scientific and oncology consultants, has developed a rational, composite formulation of anti-cancer compounds which together exert a number of anti-cancer actions. Propanc's leading products are novel, patented formulations based on proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects, Propanc intends to progress their lead product along the rigorous, formal non-clinical and clinical development pathway required to obtain regulatory approval to market its proenzyme formulation. Propanc intends to undertake development of manufacturing, formal non-clinical studies and then Phase I, II and III clinical trials in order to generate the quality, safety and efficacy data required for regulatory approval. For more information, please visit: http://www.propanc.com
http://finance.yahoo.com/news/propan...iacontentstory

$PPCH - aims to fast-track development of proenzyme-related oncology products into clinical trials, initially for colorectal and pancreatic tumors. The world market for colorectal cancer is expected to reach $8.8 billion by 2020 and the global pancreatic cancer market is projected to exceed $1.2 billion by the year 2015, according to Global Analyst Reports http://finance.yahoo.com/news/propan...iacontentstory

$PPCH - Propanc Health & its research partners identified that pancreatic proenzymes are able to suppress a long-silent, embryonic program reactivated by cancer cells, called the Epithelial Mesenchymal Transition, or EMT, by returning cancer cells back towards normal behavior. This is important because certain cancer cells develop traits such as motility, invasiveness and a resistance to readily dying. They also become "stem-cell" like and develop the ability to seed new tumors. This process, called metastasis, is responsible for approximately 90% of deaths from cancer. http://www.stockwatch.com/News/Item....=PPCH&region=U

$PPCH - after hour News on Friday- Propanc Makes Substantial Progress With Lead Patent Application for New Cancer Treatment in Key Global Regions
2014-05-23 16:00 ET - News Release
MELBOURNE, Australia, May 23, 2014 (GLOBE NEWSWIRE) -- Propanc Health Group Corporation (OTCQB:PPCH) ("Propanc" or "the Company") an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients, today announced that it has made substantial progress in connection with their ongoing efforts to secure acceptance and approval of patent applications filed around the world.

In addition to receiving grant status in South Africa, the Company has received preliminary indications from the US and European Patent Offices that key features of the Company's technology are patentable. In conjunction with its patent attorneys, the Company is in the process of responding to inquiries made by examiners from these two important jurisdictions, with a view toward securing a grant of patent in each region covering as many aspects of its technology as possible.

Together, the US and European regions account for over 60% of global pharmaceutical sales and, therefore, are the two largest global markets.

"I am pleased that our substantial efforts and pioneering research into the effects of proenzymes as a treatment against metastatic cancer have resulted in recognition by the Patent Offices in the US and Europe of the novelty of our claims," said James Nathanielsz, Propanc's Chief Executive Officer. "We will continue to work hard to protect our intellectual property to ensure we deliver maximum long term value to our shareholders," he added.
Propanc shares a joint intellectual property ownership arrangement with its research partner, the University of Bath. In addition to the United States, Europe and South Africa (where a patent already has been granted), the Company also is actively seeking patent protection in Japan, Brazil, China, Mexico, Hong Kong, Israel, Chile, Peru, Malaysia, Vietnam, Indonesia, India, Australia, New Zealand and South Korea.
About Propanc:
Propanc is a development stage healthcare company whose current focus is on the development of new cancer treatments for patients, particularly those suffering from pancreatic and colorectal cancer. Together with its scientific and oncology consultants, Propanc has developed a rational, composite formulation of anti-cancer compounds which enable and support a host of cancer treatment options. Propanc's leading products are variations upon its novel formulation and involve or employ proenzymes, which are inactive precursors of enzymes. As a result of positive early indications of the anti-cancer effects of its technology, Propanc intends to submit its principal proenzyme treatment to the rigorous, formal non-clinical and clinical development and trial processes required to obtain the regulatory approval necessary to commercialize that formulation and any product derived and/or to be derived therefrom. For more information, please visit: http://www.propanc.com
http://www.stockwatch.com/News/Item....=PPCH&region=U